Literature DB >> 27485167

Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.

Valeria Ascoli1, Giada Minelli2, Ilaria Cozzi3, Elisa Romeo4, Caterina Carnovale Scalzo5, Laura Ancona6, Francesco Forastiere7.   

Abstract

Accurate pathologic diagnosis and reporting in malignant pleural mesothelioma are essential for clinical care, and cancer registration. Practical guidelines for pathologists are provided in publications and textbooks but it is unclear how these recommendations are applied in routine practice. We investigated the characteristics of pathology reports, and the extent to which they meet guideline standards. We reviewed 819 pathology reports relating to a first diagnosis of malignant pleural mesothelioma. Data sources were a regional section of the Italian network of the Mesothelioma Registry (2001-2014) and a pathology archive (1990-2000). We evaluated tumor characteristics, the diagnosis field including terminology and immunohistochemistry (IHC) workup, and report completeness (the proportion of items recorded). We investigated also two IHC panels identified by the most used markers in current practical guidelines, one best suited for epithelioid mesotheliomas (combinations of at least 2 positive and at least 2 negative mesothelioma markers) and the other best suited for sarcomatoid mesotheliomas (positive mesothelioma markers plus cytokeratins). Reports (753 histology, 66 cytology, IHC-confirmed 86%) were 74% complete and always narrative. Missing data were related to clinical history (76%), tumor laterality (61%), specimen size (38%), and histological subtype (23%). The proportion of cases with IHC was higher for epithelioid (90%) than sarcomatoid mesothelioma (87%). Compliance to IHC recommendations was higher for epithelioid (59%) than sarcomatoid mesothelioma (11%). The mean number of stains was significantly higher for sarcomatoid than epithelioid mesothelioma (p<0.000; Kruskal-Wallis test). Our findings show that although guidelines are designed to improve actual reporting practices, there is ample room for improvement in their application to standardize the diagnosis of mesothelioma. Synoptic pathology reporting needs to be implemented to better utilize pathology information.
Copyright © 2016 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Cancer registry; Diagnosis; Immunohistochemistry; Malignant pleural mesothelioma; Pathology reporting

Mesh:

Substances:

Year:  2016        PMID: 27485167     DOI: 10.1016/j.prp.2016.07.010

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  4 in total

Review 1.  Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel.

Authors:  Alberto M Marchevsky; Andras Khoor; Ann E Walts; Andrew G Nicholson; Yu Zhi Zhang; Victor Roggli; John Carney; Anja C Roden; Henry D Tazelaar; Brandon T Larsen; Nolwenn LeStang; Lucian R Chirieac; Sonja Klebe; Ming-Sound Tsao; Marc De Perrot; Andrew Pierre; David M Hwang; Yin P Hung; Mari Mino-Kenudson; William Travis; Jennifer Sauter; Mary Beth Beasley; Françoise Galateau-Sallé
Journal:  Mod Pathol       Date:  2019-09-04       Impact factor: 7.842

2.  Malignant Pleural Mesothelioma Epidemiology in the United States From 2000 to 2016.

Authors:  Akesh Thomas; Sajin Karakattu; Jeanette Cagle; Girendra Hoskere
Journal:  Cureus       Date:  2021-04-21

Review 3.  Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge.

Authors:  David Michael Abbott; Chandra Bortolotto; Silvia Benvenuti; Andrea Lancia; Andrea Riccardo Filippi; Giulia Maria Stella
Journal:  Cancers (Basel)       Date:  2020-05-07       Impact factor: 6.639

4.  Multicellular contractility contributes to the emergence of mesothelioma nodules.

Authors:  Julia Tarnoki-Zach; Paul Stockhammer; Dona Greta Isai; Elod Mehes; Balint Szeder; Ildiko Kovacs; Edina Bugyik; Sandor Paku; Walter Berger; Sufi Mary Thomas; Zoltan Neufeld; Balazs Dome; Balazs Hegedus; Andras Czirok
Journal:  Sci Rep       Date:  2020-11-18       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.